Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk-adapted therapy of AML: the AMLCG experience.

W Kern1, T Haferlach, C Schoch

  • 1Medizinische Klinik III, Klinikum der Universität, Grosshadern, Germany.

Annals of Hematology
|May 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rehabilitation after surgical release of the stiff elbow: A literature review.

Journal of orthopaedics·2024
Same author

Role and responsibility of oncologists in assisted suicide. Practice and views among members of the German Society of Haematology and Medical Oncology.

ESMO open·2021
Same author

[Surgical treatment of snapping triceps syndrome].

Operative Orthopadie und Traumatologie·2019
Same author

Reductions in body weight and insulin resistance are not associated with changes in grey matter volume or cortical thickness during the PREVIEW study.

Journal of the neurological sciences·2019
Same author

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Leukemia·2017
Same author

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Leukemia·2017
Same journal

Clonal evolution of mycosis fungoides into peripheral T-cell lymphoma: evidence from next-generation sequencing in two cases.

Annals of hematology·2026
Same journal

Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event.

Annals of hematology·2026
Same journal

Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective study.

Annals of hematology·2026
Same journal

Flow cytometric analysis of T-cell subsets and platelet surface markers in patients with immune thrombocytopenia: a case-control study.

Annals of hematology·2026
Same journal

Lactate dehydrogenase (LDH) as a predictor of left atrial remodeling in patients with sickle cell anemia.

Annals of hematology·2026
Same journal

Pedigree analysis of cerebral venous sinus thrombosis associated with compound heterozygous hereditary protein S deficiency.

Annals of hematology·2026
See all related articles

High-dose cytarabine (AraC) during induction therapy improved outcomes for acute myeloid leukemia (AML) patients with unfavorable prognoses. This finding highlights the need for subgroup-specific AML treatments in clinical trials.

Area of Science:

  • Hematology
  • Clinical Oncology
  • Cancer Research

Background:

  • Acute myeloid leukemia (AML) is a complex disease with diverse biological subgroups.
  • Developing targeted therapies for specific AML subgroups is a key goal in modern clinical research.

Purpose of the Study:

  • To evaluate the efficacy of high-dose versus standard-dose cytarabine (AraC) in induction therapy for AML.
  • To investigate the impact of G-CSF priming and autologous stem cell transplantation versus maintenance therapy in AML treatment.

Main Methods:

  • A randomized factorial design was employed in the German AML Cooperative Group 1999 trial.
  • An interim analysis included 938 patients to assess treatment effects across different AML subgroups.

Main Results:

Related Experiment Videos

  • High-dose AraC during induction therapy demonstrated superior outcomes compared to standard-dose AraC specifically in AML patients with an unfavorable prognosis.
  • No significant difference in efficacy was observed between high-dose and standard-dose AraC in other patient subgroups.

Conclusions:

  • Treatment efficacy in AML can vary significantly based on biological subgroups.
  • Large, comprehensive clinical trials are essential for detecting therapy effects within specific AML subgroups and guiding personalized treatment strategies.